Wyeth

Pfizer Corporation

Wyeth Holdings Corporation

American Cyanamid Company

Zoetis Whc 2 LLC

Mark Edward Ruppen

Justin Keith Moran

Annaliesa Sybil Anderson

Kathrin Ute Jansen

Robert G K Donald

Michael James Flint

Maninder K Sidhu

Narender Kumar Kalyan

Jianxin Gu

Jason Arnold Lotvin

Susan Kay Hoiseth

Ping Cai

Avvari Krishna Prasad

John W Simpson

Srinivas Kodali

Nishith Merchant

Ingrid Lea Scully

Ling Chu

Eugene Joseph Vidunas

Andrew George Popplewell

Philip R Dormitzer

Nitin Krishnaji Damle

Jin-Hwan Kim

Ye Che

Xin Xu

Arthur Kunz

Xiayang Qiu

Joseph Thomas Rubino

Kena Anne Swanson

John Francis DiJoseph

Weiqiang Sun

KariAnn Sweeney Efferen

Kristin Rachael Tompkins

Lorna Del Pilar Nunez

Suddham Singh

Neera Jain

Alexey Vyacheslavovich Gribenko

Luke David Handke

Paul David Robbins

Xi Song

Bruce Arthur Green

Viliam Pavliak

Steven Morris Baker

Wei-Qiang Willie Sun

Ellen Murphy

Jasdeep Singh Nanra

Yonghui Yuan

James Patch

Yekaterina Timofeyeva

Rajesh Kumar Kainthan

Paul A Liberator

Amardeep Singh Bhupender Bhalla

Lakshmi Khandke

Haiyin He

Wei Chen

Michael Greenstein

Darren Robert Abbanat

Cindy Xudong Yang

Arthur Bailey

Rosalind Pan

Valerie Sue Bernan

Laurent Oliver Chorro

Scott Ellis Lomberk

Alan Gordon Sutherland

Ramesh Venkat Matur

Pamela S Fink

Karen Kiyoko Takane

Bo Shen

Phaik-Eng Sum

Panolil C Raveendranath

Gary Warren Zlotnick

Mahdi Bakir Fawzi

Tianmin Zhu

Russell Dushin

John Erwin Farley

Warren Chew

Subas Man Sakya

Howard Hancock Newman

Liesel A Bernfield

Chia-Cheng Shaw

Deborah Tardy Chaleff

Kiran M Khandke

Chengjin Huang

Ingrid Lea Dodge

Subas Sakya

FangMing Kong

Brian Bahler

Tsu-shun Lee

Howard Newman

Pamela Sue Fink Charbonneau

Jerome Stephens

Russ Tsao

Stanley Albert Lang

Ting-Zhong Wang

Deborah Ann Dilts

Pamela Fink Charbonneau

John McLean Simpson

Robert G Donald

Terri L Mininni

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

RSV F protein mutants

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for differentserotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

compositions and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturingand in producingtoxins.

Compositions and methods relating to a mutanttoxin

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutant clostridium difficile toxin and methods thereof

In one aspect, the invention relates to a non-lipidated and non-pyruvylatedserogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

composition and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutanttoxin and methods thereof

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B, and methods related thereto.

Non-lipidated variants ofORF2086 antigens

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Group Bpolysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Compositions and methods relating to a mutant clostridium difficile toxin

Growing community of inventors

Garnerville, NY, United States of America

Mark Edward Ruppen